Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year Low at $25.25

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares hit a new 52-week low on Thursday . The company traded as low as $25.25 and last traded at $25.34, with a volume of 11197 shares. The stock had previously closed at $25.74.

A number of equities research analysts have recently weighed in on SUPN shares. BidaskClub lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Jefferies Financial Group set a $46.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Stifel Nicolaus set a $55.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $53.38.

The stock has a market capitalization of $1.35 billion, a P/E ratio of 13.20, a price-to-earnings-growth ratio of 0.90 and a beta of 1.61. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The stock’s fifty day moving average price is $27.34 and its two-hundred day moving average price is $31.73.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The company had revenue of $104.70 million during the quarter, compared to analyst estimates of $109.67 million. During the same period in the prior year, the business posted $0.57 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. As a group, analysts expect that Supernus Pharmaceuticals Inc will post 2.16 earnings per share for the current fiscal year.

In other news, CEO Jack A. Khattar purchased 7,200 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $26.39 per share, for a total transaction of $190,008.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.57% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Patriot Financial Group Insurance Agency LLC bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $33,000. Private Capital Group LLC raised its holdings in Supernus Pharmaceuticals by 108.0% during the 2nd quarter. Private Capital Group LLC now owns 1,379 shares of the specialty pharmaceutical company’s stock valued at $83,000 after buying an additional 716 shares during the last quarter. Point72 Hong Kong Ltd raised its holdings in Supernus Pharmaceuticals by 324.1% during the 2nd quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares during the last quarter. Diversified Trust Co bought a new stake in Supernus Pharmaceuticals during the 1st quarter valued at $208,000. Finally, Redhawk Wealth Advisors Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $202,000. Institutional investors own 99.34% of the company’s stock.

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: What is a stock split?

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.